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suppresses the formation of glandular structures
and might be a predictive marker of resistance to
chemotherapy in endometrial cancer
Takuro Yamamoto†, Taisuke Mori*†, Morio Sawada, Hiroshi Matsushima, Fumitake Ito, Makoto Akiyama
and Jo KitawakiAbstract
Background: AF-6/afadin plays an important role in the formation of adherence junctions. In breast and colon
cancer, loss of AF-6/afadin induces cell migration and cell invasion. We aimed to elucidate the role of AF-6/afadin in
human endometrial cancer.
Methods: Morphology and AF-6/afadin expression in endometrial cancer cell lines was investigated by 3-dimensional
culture. We used Matrigel invasion assay to demonstrate AF-6/afadin knockdown induced invasive capability. Cell
proliferation assay was performed to estimate chemoresistance to doxorubicin, paclitaxel and cisplatin induced by
AF-6/afadin knockdown. The associations between AF-6/afadin expression and clinicopathological status were
determined by immunohistochemical analysis in endometrial cancer tissues. Informed consent was obtained from
all patients before the study.
Results: The majority of cell clumps in 3-dimensional cultures of Ishikawa cells that strongly expressed AF-6/afadin
showed round gland-like structures. In contrast, the cell clumps in 3-dimensional cultures of HEC1A and AN3CA
cells—both weakly expressing AF-6/afadin—showed irregular gland-like structures and disorganized colonies with
no gland-like structures, respectively. AF-6/afadin knockdown resulted in reduced number of gland-like structures in
3-dimensional cultures and enhancement of cell invasion and phosphorylation of ERK1/2 and Src in the highly
AF-6/afadin-expressing endometrial cancer cell line. Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656)
suppressed the AF-6/afadin knockdown-induced invasive capability. AF-6/afadin knockdown induced chemoresistance
to doxorubicin, paclitaxel and cisplatin in Ishikawa cells, not in HEC1A. Immunohistochemical analysis showed
that AF-6/afadin expression was significantly associated with myometrial invasion and high histological grade.
Conclusions: AF-6/afadin regulates cell morphology and invasiveness. Invasive capability is partly regulated through
the ERK and Src pathway. The inhibitors to these pathways might be molecular-targeted drugs which suppress
myometrial invasion in endometrial cancer. AF-6/afadin could be a useful selection marker for fertility-sparing
therapy for patients with atypical hyperplasia or grade 1 endometrioid adenocarcinoma with no myometrial
invasion. AF-6/afadin knockdown induced chemoresistance especially to cisplatin. Therefore, loss of AF-6/afadin
might be a predictive marker of chemoresistance to cisplatin.
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Endometrial cancer is one of the most common
gynecological malignancies and its incidence has in-
creased remarkably [1,2]. Endometrial cancers are broadly
classified into two groups: (1) Type 1 disease, the most
common type of endometrial cancer, is estrogen-related,
low-grade, histologically endometrioid adenocarcinoma in
most cases and shows minimal myometrial invasion and
occurs at a younger age. (2) Type 2 disease is high-grade,
histologically serous or clear cell adenocarcinoma and
shows deep myometrial invasion [3].
Cell polarity and cell-cell adhesion are essential for
normal functioning of epithelial tissues. In cancer, the
epithelial-mesenchymal transition (EMT) is a process
where epithelial cells detach from primary tumors, in-
vade into the surrounding tissues, metastasize, and grow
at a secondary site [4]. Cell-cell junctions are lost in
EMT. Most patients present with low-grade and early-
stage endometrial cancer. However, once the disease
spreads beyond the uterus, the prognosis is poor, and
the 5-year survival is 25–45% for stage III and IV [5].
Therefore, it is essential to decrease tumor invasiveness
for the treatment of endometrial cancer.
AF-6/afadin is encoded by the MLLT4 gene located on
chromosome 6, band q27 [6]. AF-6/afadin binds to nec-
tins, plays important cooperative roles in the formation
of adherens junctions, and is associated with the actin
cytoskeleton [7]. It is also important for cell polarity at
cell-cell junctions [8,9]. Conversely, AF-6/afadin at the
leading edge does not bind nectins, and enhances cell
movement [10]. Thus, AF-6/afadin has conflicting role
in cell invasion. AF-6/afadin loss induces cell migration,
invasion, and proliferation, and is a prognostic indicator
in breast and colon cancer [11-14]. However, its role and
expression in endometrial cancer have not been studied.
In this study, we investigate for the first time the expres-
sion of AF-6/afadin in patients with endometrial cancer
and its role in cell invasion and chemoresistance in
endometrial cancer.
Methods
Cell lines and materials
The Ishikawa line of human uterine endometrial cancer
cells was provided by the Cell Resource Center for
Biomedical Research (Institute of Development, Aging
and Cancer, Tohoku University, Japan). The HEC1A and
AN3CA cells were purchased from the American Type
Culture Collection. The Ishikawa and AN3CA cells were
maintained in Eagle’s MEM (Nacalai Tesque, Kyoto,
Japan) with nonessential amino acids, sodium pyruvate,
and 10% fetal bovine serum (FBS) (Invitrogen Corp.,
Carlsbad, CA). The HEC1A cells were maintained in
McCoy’s 5A (HyClone, Logan, UT) with sodium pyru-
vate, supplemented with 10% FBS. We focused onendometrioid adenocarcinoma because it was the major
type observed, and the histological grade and myome-
trial invasion are important for its diagnosis and treat-
ment. All patient samples used for this study were
obtained from University hospital, Kyoto Prefectural
University. The Kyoto Prefectural University of Medicine
human research ethics board approved all protocols and
patients gave informed consent.
RNA isolation and quantitative PCR analysis
Total RNA (1 μg) was isolated from the cells, 24 or 48 h
after siRNA transfection, using the RNeasy mini kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Each cDNA was synthesized from
1 μg RNA using the ReverTra Ace qPCR RT kit
(Toyobo, Osaka, Japan). Real-time reverse transcription-
PCR was carried out using the CFX Connect™ Real-Time
System (Bio-Rad, Hercules, CA). cDNA samples pre-
pared from the total RNA of Ishikawa, HEC1A, and
AN3CA cells (1 μL) were mixed in 20-μL reactions
containing SYBR qPCR Thunderbird master mix
(Toyobo, Osaka, Japan) and 0.2 μmol/L of each primer.
Primers, AF-6/afadin 5′-GTGGGACAGCATTACCGA
CA-3′ (forward) and 5′-TCATCGGCTTCACCATTCC-
3′ (reverse) and Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) 5′-GCACCGTCAAGGCTGAGAAC-3′
(forward) and 5′-ATGGTGGTGAAGACGCCAGT-3′
(reverse) were designed with Primer 3 software. The
amplification, detection, and data analysis were per-
formed using the CFX Connect™ Real-Time System.
Each sample was analyzed in triplicate. The expression
levels of genes were determined relative to the expres-
sion level of GAPDH.
RNA interference
Small interfering RNAs (siRNA) for MLLT4/AF-6
(s8829, s8830 and s8831) and a negative control siRNA
(control #1) targeting no known genes were Silencer®
Select siRNAs purchased from Ambion (Austin, TX).
Cells were transfected with the siRNA using Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions, and used for each experiment
after 24 or 48 h. AF-6/afadin KD effects were measured
with real-time PCR and western blotting. We decided to
use siRNA for AF-6/afadin (s8830) for the following exper-
iments, because it has the strongest KD activity of the vali-
dated siRNAs.
Three-dimensional cell culture
Cells (2.5 × 105) from the Ishikawa, HEC1A, and AN3CA
lines were trypsinized and suspended in 800 μL of BD
Matrigel™ Matrix Basement Membrane (BD biosciences,
Bedford, MA), as previously described [15]. The paraffin-
embedded specimens were cut into 3.5-μm sections for
Table 1 Association between AF-6/afadin immunoreactivity
and clinicopathological parameters in 90 uterine
endometrial cancers
AF-6/afadin immunoreactivity





Mean age (range) 55.9 (32–83) 58.6 (28–80) 0.41
Histological type
Endometrioid 51 (100%) 34 (87.2%)
Serous 0 3 (7.7%)







1 38 (74.5%) 11 (32.4%)
2 11(21.6%) 13(38.2%)
3 2 (3.9%) 10 (29.4%) P < 0.01
Myometrial invasion
No invasion 14 (27.5%) 1 (2.9%)
Less than half 26 (51.0%) 15 (44.1%)
More than half 11 (21.6%) 18 (52.9%) P < 0.01
Lymph node metastasis
Negative 48 (94.1%) 30 (88.2%)
Positive 3 (5.9%) 4 (11.8%) 0.57
Stage
I 37 (72.5%) 25 (73.5%)
II 7 (13.7.8%) 2 (5.9%)
III 6 (11.8%) 6 (17.6%)
IV 1 (2.0%) 1 (2.9%) 0.82
Cases with H-score > 50 are positive.
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chemical staining. Each experiment was performed three
times.
Matrigel invasion assay
Cells (2.0 × 105) were seeded into the top of a Matrigel
invasion chamber (24-well insert; pore size, 8 μm; BD
Biosciences, Bedford, MA) containing a serum-free and
a medium with 10% FBS was used as a chemoattractant
in the lower chamber. The cells were incubated for 48 h
at 37°C. A cotton swab was used to remove the cells,
that did not invade through the pore and cells that had
migrated to the lower surface of the membrane were
stained with the Diff-Quik kit (Sysmex, Kobe, Japan) and
counted.
Cell proliferation assay
Cells (5.0 × 103) were seeded into 96-well plates contain-
ing a normal growth medium, and RNA interference
was performed after 24 h. The anticancer drugs were
added at various doses, 24 h after siRNA transfection.
The cells were cultured and treated in quadruplicate,
and cell viability was examined after 72 h by the 2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
phonyl)-2H-tetrazolium (WST-8) assay (Nacalai Tesque,
Kyoto, Japan).
Antibodies
A mouse anti-AF-6/afadin antibody (clone 35) was
purchased from Becton Dickinson. A mouse anti-Src
antibody (# 2110) and rabbit anti-GAPDH (# 2118),
anti-ERK1/2 (# 9102), anti-phospho-ERK1/2 (Thr202/
Tyr204), and anti-phospho-Src family (Tyr416) (# 2101)
antibodies were purchased from Cell Signaling Technology
(Beverly, MA). All antibodies were used at the concentra-
tion recommended by the manufacturers.
Western blotting
Cells were washed twice in phosphate-buffered saline and
lysed in RIPA buffer (Nacalai Tesque, Kyoto, Japan).
Cell lysates (20 μg) were heated in sodium dodecyl sul-
fate (SDS) sample buffer (125 mM Tris–HCl, pH 6.8, 4%
SDS, 25% glycerol, 10% 2-mercaptoethanol, 0.05 mM
phenylmethanesulfonyl fluoride and 0.004% bromophe-
nol blue), separated using 10% e-PAGEL according to
the manufacturer’s recommendations (Atto Corp, Tokyo,
Japan), and transferred onto Immuno-Blot® PVDF mem-
branes (Bio-Rad, Hercules, CA). The membranes were
blocked in Tris-buffered saline supplemented with 5%
fat-free milk for 1 h and then incubated with indicated
antibodies at 4°C overnight. After washing, the mem-
branes were incubated with the secondary antibody for
1 h at room temperature. The signal was developed
using Chemi-Lumi One Super (Nacalai Tesque, Kyoto,Japan) and analyzed by a ChemiDoc XRS system with
Image Lab software (Bio-Rad, Hercules, CA).
Immunohistochemistry
Specimens from patients who underwent abdominal hys-
terectomy because of uterine endometrial cancer were
used for this study. Informed consent was obtained from
all the patients before the study was conducted. The
protocol has been previously described [16]. The AF-6/
afadin immunoreactivities were scored using a semi-
quantitative index, the H-score. The H-score is the
product of the intensity of staining (given a value of 0, 1,
2, or 3 for negative, weak, moderate, or strong, respect-
ively) and the percentage of stained epithelial cells at
each intensity (0–100%). Samples with H-score ≥ 50 were
deemed as AF-6/afadin-positive.
Statistical analysis
Progression-free survival and overall survival were
assessed using the Kaplan-Meier method and log-rank
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data between two groups were performed using the
Student’s t test. Comparisons of over 3 groups were per-
formed using the Kruskal-Wallis H-test, and the Mann–
Whitney U-test with Bonfferoni correction was as a post
hoc test. Statistical differences between AF-6/afadin sta-
tus and histological type, histological grade, myometrial
invasion, lymph node status, and stage were evaluated
using a chi-square test. P values < 0.05 were considered
significant.
Results
Low expression levels of AF-6/afadin in uterine endometrial
cancer tissues were associated with myometrial invasion
and high histological grade
All sections of normal endometrium stained positive for
AF-6/afadin. AF-6/afadin was expressed in the cyto-
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Figure 1 Association of AF-6/afadin expression with histological grade and
staining values of 0, 1, 2, or 3 are negative, weak, moderate, or strong, r
associated with high histological grade (between grade 1 and 2 cases, a
and deep myometrial invasion (between no invasion and more than ha
H-score and histological grade or myometrial invasion were assessed with
correction was used as a post hoc test. Significant differences were indicaassociation between AF-6/afadin immunoreactivity and
clinicopathological status are shown in Table 1. Of the
90 endometrial cancer cases, 85 cases were endometrioid
adenocarcinomas.
The H-score of AF-6/afadin was significantly associ-
ated with histological grade (between grade 1 and 2
cases, and between grade 1 and 3 cases, P < 0.01) and
myometrial invasion (between cases with no invasion
and cases with a myometrial invasion depth of more
than 50%, P < 0.01) in endometrioid adenocarcinoma
(Figure 1b, c). The H-score of the normal endometrium
(n =10) was significantly higher than that of the
endometrioid adenocarcinoma (between normal endo-
metrium and grade 1, P < 0.05, and between normal
endometrium and grade 2, and 3, P < 0.01) (Figure 1b).
However, there were no significant associations between
the AF-6/afadin immunoreactivity and the FIGO stage,










































re P = 0.0578
myometrial invasion in 85 endometrioid adenocarcinomas. (a) The
espectively. (b, c) Low H-score of AF-6/afadin immunoreactivity was
nd between grade 1 and 3 cases, P < 0.01, and 0.01, respectively)
lf invasion cases, P < 0.01) (b). The correlations between AF-6/afadin
the Kruskal-Wallis H-test; the Mann–Whitney U-test with Bonfferoni
ted as * for P < 0.05 and ** for P < 0.01.
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OS, respectively).
AF-6/afadin plays an important role in 3-dimensional
cultures of Ishikawa, HEC1A, and AN3CA cells
To investigate AF-6/afadin expression and morphology,
3-dimensional (3D) culture was performed. AF-6/afadin
mRNA level in 3D cultures was significantly higher than
that in monolayer cultures in Ishikawa cells (P < 0.01),
similar to that in monolayer cultures in the HEC1A, and
significantly lower than that in monolayer cultures in
AN3CA cells (P < 0.01) (Figure 2a). AF-6/afadin immu-
nostaining was strongly, weakly, and very weakly positive
in the Ishikawa, HEC1A, and AN3CA cells, respectively.
The majority of the cell clumps in 3D cultures of Ishi-
kawa cells showed round gland-like structures, whereas
the cell clumps in 3D cultures of HEC1A and AN3CA
showed irregular gland-like structures and disorganized
colonies with no gland-like structures, respectively
(Figure 2b). RNA interference experiments to knock-
down (KD) AF-6/afadin and subsequent 3D cultures
were performed using the Ishikawa cells. In this assay,
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Figure 2 Three-dimensional (3D) cultures of Ishikawa, HEC1A, and AN3CA
HEC1A, and AN3CA cells, standardized with GAPDH. AF-6/afadin mRNA lev
(Mono) culture in the Ishikawa cells, remained unchanged from that in Mo
Mono culture in the AN3CA cells. Significant difference were indicated as *
showed that Ishikawa, HEC1A, and AN3CA cells were strongly positive, wea
the cell clumps formed round gland-like structures in 3D cultures of Ishikaw
gland-like structures and in the form of disorganized colonies with no glanAF-6/afadin KD was still maintained. AF-6/afadin KD
increased the number of disorganized colonies and re-
duced the number of gland-like structures in 3D cul-
tures of Ishikawa cells (P < 0.01) (Figure 3).
AF-6/afadin KD induced phosphorylation of ERK1/2
and Src kinase and stimulated cell invasion in
AF-6/afadin-positive cell lines
First, we evaluated whether AF-6/afadin regulates cell
migration and invasion in endometrial cancer, using
trans-well cell culture inserts and the Matrigel Invasion
chamber system. We used Ishikawa (AF-6/afadin strong
positive) cells and HEC1A (AF-6/afadin weak positive)
cells. AF-6/afadin KD cells significantly enhanced the in-
vasive capability in the Ishikawa and HEC1A compared
with negative control cells (P < 0.05) (Figure 4a-d); how-
ever, although the migratory capability was examined
using Trans-well cell culture inserts without Matrigel
coating, it remained unchanged (data not shown).
We next investigated how AF-6/afadin KD stimulates
invasive capability. In Ishikawa cells, AF-6/afadin KD
induced phosphorylation of ERK1/2 and Src kinases.
Conversely, in HEC1A cells, ERK1/2 and Src kinase wereAfadin
EC1A
AN3CA1A
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cells. (a) Real-time RT-PCR for AF-6/afadin using cDNA from Ishikawa,
els in 3D culture were significantly higher than that in monolayer
no culture in the HEC1A cells, and was significantly lower than that in
* for P < 0.01. (b) AF-6/afadin immunohistochemistry of 3D culture
kly positive and very weakly positive, respectively. A large portion of
a cells, whereas in 3D cultures of HEC1A and AN3CA cells, irregular
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Figure 3 Morphology change induced by AF-6/afadin KD in the Ishikawa cells in 3D culture. The paraffin-embedded samples were cut into
3.5-μm sections. Immunohistochemistry was performed to confirm the efficacy of AF-6/afadin KD (data not shown) and (a) we also examined
AF-6/afadin KD efficacy by western blotting. (b, c) The morphological differences in 3D cultures were assessed by hematoxylin-eosin staining.
The KD control Ishikawa cells mainly formed the glands like structures. Panel (c) is the magnification of the box in (b). (d, e) AF-6/afadin KD
Ishikawa cells mainly formed disorganized colonies. Panel (e) is magnification of the box in (d). (f) The number of gland-like structures per 100
cell clumps was counted three times. AF-6/afadin KD significantly reduced the number of gland-like structures. Significant differences were
indicated as ** for P < 0.01.
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cantly increase the level of phosphorylated ERK1/2 or
Src (Figure 4e). This result indicates that AF-6/afadin
functions as a suppressor of ERK and Src phosphoryl-
ation pathways. Using the MEK inhibitor (U0126) and
the Src kinase inhibitor (SU6656), we demonstrated the
importance of ERK1/2 and Src phosphorylation for regu-
lating the cell invasion induced in the Ishikawa cells by
AF-6/afadin KD. First, we determined the concentrations
of U0126 and SU6656 (5 μM and 1 μM, respectively). At
the determined concentrations, the reagents inhibited
phosphorylation of ERK1/2 and Src, and did not influ-
ence the proliferation of the Ishikawa cells (data not
shown). At these concentrations, U0126 and SU6656
significantly inhibited Ishikawa cell invasions induced byAF-6/afadin KD (Figure 5). This result indicates that
AF-6/afadin KD induced cell invasion through ERK and
Src signaling pathways.
AF-6/afadin KD induced chemoresistance to doxorubicin,
paclitaxel and cisplatin in AF-6/afadin strongly positive
cell line
To estimate chemoresistance to doxorubicin, paclitaxel
and cisplatin induced by AF-6/afadin KD, we performed
the WST-8 assay cell proliferation assay using. In
Ishikawa cells, AF-6/afadin KD induced slight chemore-
sistance to doxorubicin and paclitaxel, and strong resist-
ance to cisplatin (Figure 6a-c, respectively). However,















































































Figure 4 Invasiveness of Ishikawa cells is enhanced by AF-6/afadin KD through phosphorylation of ERK1/2 and Src. Invasiveness was evaluated
using the Matrigel invasion assay. For this assay, siRNA for control or AF-6/afadin was transfected into the Ishikawa or HEC1A cells. (a-d)
The number of invasive cells increased significantly in AF-6/afadin KD Ishikawa and HEC1A cells. Significant differences are indicated as * for
P < 0.05. (e) Expression of GAPDH was used as the internal control. Using siRNA-negative control or siRNA against AF-6/afadin, AF-6/afadin
was effectively knocked down at the protein level. AF-6/afadin KD induced phosphorylation of ERK1/2 and Src in the Ishikawa cells, whereas
expression of phosphorylated ERK1/2 and Src was already strong and was not up-regulated by AF-6/afadin KD in HEC 1A cells.
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AF-6/afadin is expressed in almost all normal epithe-
lial tissues where it is involved in forming the actin
cytoskeleton by binding actin filaments and nectins
(immunoglobulin-like cell adhesion molecules) [17].
AF-6/afadin, in cooperation with nectins, involved in
the formation of a variety E-cadherin-dependent or
E-cadherin-independent cell-cell junctions [7,9,18,19].
Decreased E-cadherin expression is associated with
poor prognosis, high histological grade and advanced
stage in endometrial cancer [20-22]. Immunohisto-
chemical analysis revealed that AF-6/afadin expres-
sion in endometrial cancer tissues was lower than
that in normal endometrial tissues. Furthermore, loss
of AF-6/afadin expression was associated with myo-
metrial invasion and high histological grade in pa-
tients with endometrial cancer.
Three-dimensional cell culture is a useful model to
investigate molecular signaling and cellular behavior
during epithelial morphogenesis [23]. In this study,
when comparing the mRNA levels in monolayer and
3D cultures, the mRNA levels of nectins in both cul-
tures were found to be similar, while AF-6/afadin
mRNA levels in well-differentiated and poorly differ-
entiated endometrial cancer cell lines were higher and
lower, respectively, in the 3D cultures. These resultssuggest that AF-6/afadin could be an important scaf-
fold protein determining epithelial morphogenesis in
uterine endometrial cancer.
AF-6/afadin was strongly expressed in Ishikawa cells, a
well-differentiated and grade 1 equivalent endometrial
adenocarcinoma cell line, whereas AF6/afadin was
weakly expressed in HEC1A and AN3CA cells, which
are derived from grade 2 and grade 3 endometrial
adenocarcinomas, respectively. In 3D cultures, AF-6/
afadin expression was positively associated with the
formation of round gland-like structures. AF-6/afadin
was expressed in all normal endometrial tissues and
most well-differentiated endometrial adenocarcinomas
in our study. Therefore, we investigated the function
of AF-6/afadin using an RNA interference assay. In
endometrioid cancers, histological grade is defined in
terms of solid tumor growth; increased solid growth
is associated with high histological grade and a high
degree of cellular atypia [24]. AF-6/afadin KD re-
sulted in fewer gland-like structures and more disor-
ganized colonies in Ishikawa cell cultures than in the
KD control cultures. This result explains why AF-6/
afadin loss was associated with higher histological
grade. AF-6/afadin KD significantly enhanced cell in-
vasion in AF-6/afadin-positive endometrial cancer cell
lines. These results suggest that AF-6/afadin serves
Control with DMSO
AF-6 KD with DMSO
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Figure 5 Effect of U0126 and SU6656 on invasiveness induced by AF-6/afadin KD in the Ishikawa cells. (a, c) AF-6/afadin KD enhanced cell
invasion and U0126 inhibited the invasive capability of Ishikawa cells. (b, d) SU6566 also showed the inhibitory effect.
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tor of tissue invasion in human endometrial cancer.
We focused on the cell signaling pathways induced by
AF-6/afadin KD to determine the mechanisms under-
lying these findings. A Src signaling is important in mul-
tiple physiological homeostatic pathways that regulate
cell proliferation, cell survival, cytoskeleton regulation,
intracellular contacts, cell-matrix adhesion, motility, and
migration [25,26]. An Src mutation at codon 537 was
previously detected in a small subset of endometrial can-
cers [27]. In this study, we demonstrated that enhance-
ment of phosphorylation in the Src kinase family was
induced by AF-6/afadin KD in the strongly AF-6/afadin-
positive Ishikawa cells. The AF-6/afadin KD-induced in-
vasiveness of the Ishikawa cells was repressed by
SU6656, an Src inhibitor. These findings indicate that
AF-6/afadin might regulate cell invasion through the Src
signaling pathway.
RAS/RAF/MEK/ERK pathways are also important for
cell proliferation and survival in several cancers [28-33].AF-6/afadin links to Bcr and RAS and down-regulates
RAS-dependent stimulation of the RAF/MEK/ERK sig-
naling pathway [34]. The activation of ERK1/2 induced
by AF-6/afadin KD has been reported in breast cancer
[12]. We also found that AF-6/afadin KD increased
phosphorylation of ERK1/2 proteins. In addition, U0126,
a MEK inhibitor, also suppressed AF-6/afadin KD in-
duced phosphorylation of ERK1/2 and cell invasion in
endometrial cancer. These results also suggest that AF-
6/afadin KD induced cell invasion through the RAF/
MEK/ERK signaling pathway.
Chemoresistance is an important problem in cancer
therapy. The ERK pathway has been implicated in che-
moresistance to doxorubicin, paclitaxel and cisplatin in
some cancers [35-39], although the findings are contro-
versial. AF-6/afadin KD increased the phosphorylation
of ERK 1/2 in Ishikawa cells, but not in HEC1A cells.
AF-6/afadin KD also induced chemoresistance to doxo-
rubicin, paclitaxel, and cisplatin in AF-6/afadin strongly




































































































































































































Figure 6 AF-6/afadin KD-induced chemoresistance to doxorubicin, paclitaxel, and cisplatin induced. Blue lines show proliferation of cells transfected
with control siRNA, and red lines show AF-6/afadin KD. (a-c) AF-6/afadin KD induced slight chemoresistance to doxorubicin and paclitaxel, and strong
chemoresistance to cisplatin in Ishikawa cells (d-f); however, it did not induce chemoresistance in HEC1A cells.
Yamamoto et al. BMC Cancer  (2015) 15:275 Page 9 of 10ERK pathway could be involved in the chemoresistance
induced by AF-6/afadin KD.
Conclusions
In this study, we demonstrated that AF-6/afadin regu-
lates cell invasion through ERK and Src pathway. The
inhibitors to these pathways might be molecular-
targeted drugs which suppress myometrial invasion in
endometrial cancer. AF-6/afadin is an important scaffold
protein and might be crucial for maintenance of the
ductal structure of glands in the endometrium. Reduced
expression of AF-6/afadin is associated with high histo-
logical grade and myometrial invasion of endometrial
cancers. AF-6/afadin could be a useful selection marker
for fertility-sparing therapy for the patients with atypical
hyperplasia or grade 1 endometrioid adenocarcinoma
with no myometrial invasion. AF-6/afadin KD induced
strong chemoresistance to cisplatin. Therefore, loss ofAF-6/afadin might be a predictive marker of chemoresis-
tance to cisplatin.
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